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This article present data related to the publication entitled “Native
and myeloperoxidase-oxidized low-density lipoproteins act in
synergy to induce release of resolvin-D1 from endothelial cells”
(Dufour et al., 2018). The supporting materials include results
obtained by Mox-LDLs stimulated macrophages and investigation
performed on scavenger receptors. Linear regressions (RvD1 vs age
of mice and RvD1 vs CL-Tyr/Tyr) and Data related to validationvier Inc. This is an open access article under the CC BY license
atherosclerosis.2018.03.012









D. Dufour et al. / Data in Brief 18 (2018) 1160–1171 1161were also presented. The interpretation of these data and further
extensive insights can be found in Dufour et al. (2018) [1].
& 2018 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Specifications tableSubject area Biochemistryore specific subject area Resolvin D1 in atherosclerosis
ype of data Table, text file, graph, figure
ow data was acquired Mass spectrometry (LC-MS-/-MS system from Agilent Technologies
(Santa Clara, CA, USA): an Agilent 1290 Infinity Binary - UHPLC
system coupled to a mass spectrometer Agilent Jet Stream electro-
spray ionization source (AJS)-Triple Quadrupole (QQQ) 6490 series)
Rt-PCRata format Analyzed
xperimental factors Samples were treated by liquid-liquid extraction before analysis
xperimental features RvD1 and precursors (17S-HDHA and DHA) were quantified in cell
supernatant or in plasma.
ata source location Brussels, Belgium
ata accessibility The data are provided with this articleD
Value of the data
 Validation of method was an important part of this work and we showed how it was developed.
 Data show how scavenger receptors, usually involved in oxidized LDLs recognition, were analyzed
and how they could be involved in RvD1 synthesis.
 Correlation was established between level of RvD1 and Cl-Tyr/Tyr ratio from healthy donors and
between level of RvD1 and age in mice. These results are illustrated here.
 Because HMEC have shown ability to produce RvD1, we assay the production of RvD1 by mono-
cytes (THP-1).1. Data
Different aspects of method validation for RvD1 and precursors analysis were described. Moreover,
we investigated many aspects of RvD1 mechanistic of production linked to Mox-LDLs stimulation of
endothelial cells and THP-1 macrophages.
1.1. Macrophages are apparently not essential for RvD1 production
It is generally accepted that EC and monocytes/macrophages are both required to produce RvD1.
However, it was shown that EC are able to produce RvD1 alone [1]. Therefore, we tested whether

































































































































































Fig. 1. (A), (B), (C): Incubation of THP-1: Data for RvD1 (A), 17S-HDHA (B) and DHA (C) after 24 h of incubation of THP-1 with
Ox-LDLs, Mox-LDLs or LDLs-nat with (light grey bars) or without (dark grey bars) supplementation of 10 ng/ml 17S-HDHA and
DHA. Data are expressed as mean 7 SD of four independent experiments compared to the average of four controls (control
RvD1: 0.02 7 0.01 ng/ml; 17S-HDHA: 0.26 7 0.05 ng/ml; DHA: 21 7 2 ng/ml).
D. Dufour et al. / Data in Brief 18 (2018) 1160–11711162Mox-LDLs and data showed an increased concentration of RvD1 (76 7 21 pg/ml) compared with
THP-1 cells incubated with 100μg/ml non-physiologic Ox-LDLs (RvD1 35 7 16 pg/ml) or 100 μg/ml
LDLs-nat (RvD1 14 7 10 pg/ml). However, the differences were not statistically significant. An
increase in 17S-HDHAwas also observed in the same conditions with a concentration of 439 7 32 pg/
ml when incubated with 100 μg/ml of Mox-LDLs and concentrations of 192 7 84 pg/ml and 202 7
25 pg/ml when incubated with Ox-LDLs or LDLs-nat, respectively. These data were again not statis-
tically significant (see Fig. 1).2. Experimental design, materials and methods
2.1. Macrophages are apparently not essential for RvD1 production
Because we suspected that THP-1 may participate in RvD1 production, we also tested the effects of
Mox-LDLs, non-physiologic Ox-LDLs and LDLs-nat on the synthesis of RvD1 and 17S-HDHA by THP-1.
Fig. 2. (A), (B), (C): Chromatograms obtained by LC/MS-MS analysis of RvD1 from plasma of healthy donor without supple-
mentation (A) or spiked by 0.5 ng/ml of standard (B) and compared to Internal standard RvD1-d5 (C).



























































































































































Fig. 3. (A), (B), (C): Effect of lipeamia on quantification of RvD1, 17S-HDHA and DHA: Quantification of RvD1 (A), 17S-HDHA
(B) and DHA (C) in sample of plasma from healthy donor, spiked by RvD1, 17S-HDHA and DHA (0.5 ng/ml, 5 ng/ml and 100 ng/
ml respectively) and by different concentration of LDLs-nat (0, 250, 500 µg/ml). Data are expressed as mean 7 SD of four
independent experiments compared to the average of four controls obtained with by plasma not spiked (control RvD1: 0.03 7
0.01 ng/ml; 17S-HDHA: 0.62 7 0.04 ng/ml; DHA: 566 7 48 ng/ml). * p o 0.05; ** p o 0.01 and *** p o 0.001 by Tukey Test.


































































































































Fig. 4. (A), (B), (C): RvD1 by MPO system stimulation of HMEC: concentrations (ng/ml) obtained for RvD1 (A), 17S-HDHA
(B) and DHA (C) after stimulation of HMEC by MPO system, Angiotensine II, Mox-LDLs or HOCl.
D. Dufour et al. / Data in Brief 18 (2018) 1160–1171 1165THP-1 were incubated with 200 μg/ml of Mox-LDLs, LDLs-nat or non-physiologic Ox-LDLs. The effect
of supplementation with 10 ng/ml of DHA and 17S-HDHA was also tested. Samples were purified by
the previous method and RvD1, 17S-HDHA and DHA were quantified using LC-MS/MS as illustrated in
Fig. 1 (Figs. 2–12). The quantification of RvD1 and precursors was tested in the presence of different
LDL concentrations (see Fig 2). For details on the method validation, see Dufour et al. (2018) and
tables 1 and 2. This method was used for quantification of RvD1 and precursors in different matrices



























































































































































Fig. 5. (A), (B), (C): Effect of LDLs-nat, HDLs and Mox-LDLs on HMEC: Quantification of RvD1 (A), 17S-HDHA (B) and DHA (C) in
supernatants of cells stimulated by LDLs-nat (1000 µg/ml), HDLs (1000 µg/ml) and Mox-LDLs (200 µg/ml) for 24 h at 37 °C. Data
are expressed as mean 7 SD of four independent experiments. Control was carried out on by HMEC alone.
Fig. 6. Validation of LDLR gene silencing efficiency using siRNA: RNA was extracted and analyzed by qRT-PCR. Expression levels were
normalized to GAPDH. Values are expressed as fold change compared to the control. Data were evaluated by One-Way ANOVA test
* p o 0.05.





































































































































































































































































































Fig. 7. (A), (B), (C): Control of integration of Mox-LDL or Ox-LDL by LDL receptor: Relative response of RvD1 (A), 17S-HDHA
(B) and DHA (C) calculated after incubation of endothelial cells with SiRNA LDLr, SiRNA SCARB1, SiRNA LOX-1 or all SiRNA
pooled in presence of Mox-LDL or Ox-LDL (100 µg/ml). Controls were realized by endothelial cells without transection or
transfected by scrambled siRNA.
D. Dufour et al. / Data in Brief 18 (2018) 1160–1171 1167
Fig. 8. (A), (B), (C): Validation of gene silencing efficiency using siRNA: HMEC-1 cells were transfected with scrambled siRNA
(sc siRNA) or LDLR siRNA for 48 h then treated with Mox-LDL or OxLDL (100 µg/ml) for another 24 h. RNa was then extracted
and analyzed by qRT-PCR using primers specific for LDLR. The expression level was normalized to GAPDH. Values are expressed
as the fold change to the control. Data were evaluated by one-way ANOVA test: * p o 0.05, ** p o 0.01 and *** p o 0.001 vs
control were considered significant.
D. Dufour et al. / Data in Brief 18 (2018) 1160–117111682.2. in vivo macrophage subpopulations analysis using flow cytometry
100 µL of total blood were incubated for 15min at RT with PE mouse anti-human CD14 and V500
mouse anti-human CD16 antibodies (Becton Dickinson, Franklin Lakes, NJ, USA) as well as with mouse
anti-human CD86-FITC and anti-human CCR2-APC monoclonal antibodies (Miltenyi Biotec, Bergisch
Gladbach, Germany) for determining the M1 polarization or with mouse anti-human CD206-FITC,
anti-human CXCR3-APC and anti-human CD163-VioBlue monoclonal antibodies (Miltenyi Biotec,
Bergisch Gladbach, Germany) for the M2 polarization. Red blood cells were then eliminated by adding
BD FACS Lysing Solution (dilution: 1/20) (Becton Dickinson, Franklin Lakes, NJ, USA) to total blood and
remaining cells were washed twice with 1 mL of running buffer. Cells were finally resuspended in 300
µL of running buffer for analysis. The matching isotype controls were used for each antibody in order
to define the threshold. The analysis was performed using the MACSQuant Analyzer 10 (Miltenyi
Biotec, Bergisch Gladbach, Germany), applying a gating strategy based on the SSC vs PE gate (CD14),





















































































































































































































Fig. 9. (A), (B), (C): Effect of time on SiRNA LOX-1: Relative intensity of RvD1 (A), 17S-HDHA (B) and DHA (C) calculated by
normalization to control after incubation of endothelial cells with SiRNA LOX-1 in presence of Mox-LDL or Ox-LDL (100 µg/ml)
for 24 h or 48 h. Controls were realized by endothelial cells without transection.
D. Dufour et al. / Data in Brief 18 (2018) 1160–1171 1169
Linear reg. RvD1 vs age of mice










Fig. 11. Linear regression of RvD1 versus age of mice s (n ¼ 65, ♀ ¼ 40, ♂¼ 25, middle age ¼ 291 7 270 days, R2 ¼ 0.08782,
p ¼ 0.0165, slope ¼ −0.00006673 to −0.000006936).
linear reg. RvD1 vs Cl-Tyr/Tyr











Fig. 12. Linear regression of RvD1 versus ratio Chloro-tyrosine/tyrosine from healthy donors (n ¼ 23, R2 ¼ 0.1809, p ¼ 0.0430,
slope ¼ −0.0001060 7 0.00004921).
******
Fig. 10. Quantification of RvD1 after 24 h of incubation of endothelial cells with DMSO (vehicle), DPI (NADHP oxidase and NOS
inhibitor), ML351 (lipoxygenase inhibitor), MAFPF (PLA2 inhibitor), dexamethasone (anti-inflammatory), water (vehicle) Trolox
(antioxidant) in presence of Mox-LDL compared to a control. Data are given as relative response normalized of 4 independent
experiments. Data were considered as significant (MAFP vs DMSO and Trolox vs Water) by ANOVA: p o 0.001 (***).
D. Dufour et al. / Data in Brief 18 (2018) 1160–11711170CD14 and a low expression of CD16 (CD14þCD16-). Intermediate monocytes were defined based on a
high expression of CD14 and CD16 (CD14þCD16þ), while non-classical monocytes were character-
ized by a low expression of CD14 and a high expression of CD16 (CD14-CD16þ) (Tables 1–3).
Table 1
Transitions optimization: Transitions associated to collision energy used like quantifier or qualifier and retention time in
minutes for each compound. These transitions were obtained using Optimizer program from Agilent Technologies and were
confirmed by manual optimization.






RvD1 375.22 141.1 (16 eV) 215.1 (16 eV) 4.8
RvD1-d5 380.25 141.1 (13 eV) 220 (17 eV) 4.8
17S-HDHA 343.23 281.3 (8 eV) 325.3 (8 eV) 7.0
PGE2-d4 355.2 319.1 (4 eV) 275.2 (12 eV) 4.5
DHA 327.23 283.2 (8 eV) 58.9 (40 eV) 8.2
DHA-d5 332.26 288.0 (5 eV) 234.3 (9 eV) 8.2
Table 2
Data of validation: Recovery and coefficients of variation (CV) obtained using liquid/liquid purification of plasma spiked with
two different concentrations of RvD1 (1 ng/ml and 0.5 ng/ml), 17S-HDHA (10 ng/ml and 5 ng/ml) and DHA (200 ng/ml and
100 ng/ml).
Product Concentration (ng/ml) Recovery (%) CV (%)
RvD1 1 86.1 7 8.1 9.4
0.5 90.2 7 3.1 3.4
17S-HDHA 10 45.2 7 12.0 26.5
5 53.0 7 7.7 14.6
DHA 200 100.1 7 13.2 13.2
100 104.5 7 5.4 5.2
Table 3
List of primers: primers used for qRT-PCR.
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